







Home ▶ All Journals ▶ Medicine ▶ Current Medical Research and Opinion ▶ List of Issues ▶ Volume 25, Issue 7 ▶ Projected economic impact of clinical fi ....

Current Medical Research and Opinion > Volume 25, 2009 - Issue 7

241 11

Views CrossRef citations to date Altmetric

Original Article

# Projected economic impact of clinical findings of generic entry of topiramate on G4 European countries

Pierre Emmanuel Paradis, Dominick Latrémouille-Viau, Yuliya Moore, Natalia Mishagina, Marie-Hélène Lafeuille, Patrick Lefebvre, ...show all

Pages 1793-1805 | Accepted 15 May 2009, Published online: 05 Jun 2009

**66** Cite this article ▲ https://doi.org/10.1185/03007990903044374

> Sample our to the latest two volumes for 14 days

Full A

Repri

ABSTE

Objectiv

topiram

of Fra impa

† Topam

**USA** 

Researc

Ouébec

**Patients** 

design was used

### We Care About Your Privacy

We and our 907 partners store and access personal data, like browsing data or unique identifiers, on your device. Selecting "I Accept" enables tracking technologies to support the purposes shown under "we and our partners process data to provide," whereas selecting "Reject All" or withdrawing your consent will disable them. If trackers are disabled, some content and ads you see may not be as relevant to you. You can resurface this menu to change your choices or withdraw consent at any time by clicking the ["privacy preferences"] link on the bottom of the webpage [or the floating icon on the bottom-left of the webpage, if applicable]. Your choices will have effect within our Website. For more details, refer to our Privacy Policy. Here

We and our partners process data to provide:

I Accept

Reject All

**Show Purpose** 

drug (AED)

ne settings

economic

isville, NJ,


ladie du re used.

en-cohort

**b**randed

versus generic use of topiramate. Canadian healthcare utilization and costs (2007 CAN\$/person-year) were compared between periods using multivariate models. Annualized per-patient costs (2007€ or 2007£/person-year) were converted using Canadian utilization rates, European prices and service-use ratios. Non-parametric bootstrap served to assess statistical significance of cost differences. Topiramate market was forecasted following generic entry (09/2009–09/2010) using autoregressive models based on the European experience. The economic impact of generic topiramate entry was estimated for each country.

Results: A total of 1164 patients (mean age: 39.8 years, 61.7% female) were observed for 2.6 years on average. After covariates adjustment, generic-use periods were associated with increased pharmacy dispensings (other AEDs: +0.95/person-year, non-AEDs: +12.28/person-year, p < 0.001), hospitalizations ( + 0.08/person-year, p = 0.015), and lengths of hospital stays (+0.51 days/person-year, p < 0.001). Adjusted costs, excluding topiramate, were CAN\$1060/person-year higher during generic use (p = 0.005). Converted per-patient costs excluding topiramate were significantly higher for generic relative to brand periods in all European countries (adjusted cost differences per person-year: €706-815, p < 0.001 for all comparisons). System-wide costs would increase from 3.5 to 24.4% one year after generic entry.



Declar

This ana

Pharmaceucica iv

### Declaration of financial/other relationships

M.G. has disclosed that she is an employee of Janssen-Cilag EMEA. All other co-authors disclosed that they are employees of Analysis Group, Inc., which has received research grants to conduct this study from Janssen-Cilag EMEA.


All peer reviewers receive honoraria from CMRO for their review work. Peer reviewer 1 disclosed that he/she has received grant support from GlaxoSmithKline. Peer reviewer 2 disclosed that he/she has no relevant financial relationships.

## Acknowledgment

Janssen-Cilag EMEA participated in the design, review, and approval of the manuscript.

The authors disclosed no further assistance in preparation of this manuscript.

### Notes



Economic impact of generic substitution of lamotrigine: projected costs in the US using findings in a Canadian setting Source: Current Medical Research and Opinion Are there potential problems with generic substitution of antiepileptic drugs? Source: Seizure Compulsory Generic Switching of Antiepileptic Drugs: High Switchback Rates to Branded Compounds Compared with Other Drug Classes Source: Epilepsia Therapeutic equivalency of generic antiepileptic drugs: results of a survey Source: Epilepsy & Behavior Clinical consequences of generic substitution of lamotrigine for patients with epilepsy Source: Neurology Do Drugs Reduce Utilisation of Other Healthcare Resources? Source: PharmacoEconomics Bias and causal associations in observational research Source: The Lancet Outbreak of Anticonvulsant Intoxication in an Australian City Source: BMI Patient and physician reactions to generic antiepileptic substitution in the treatment of epilepsy Source: Epilepsy & Behavior Cost of refractory epilepsy in adults in the USA Sourc X Who' ies Sourc Linkir Share

Information for Open access Authors Overview R&D professionals Open journals Editors **Open Select** Librarians **Dove Medical Press** Societies F1000Research Opportunities Help and information Reprints and e-prints Advertising solutions Newsroom Accelerated publication Corporate access solutions Books Keep up to date Register to receive personalised research and resources by email Sign me up X or & Francis Group Copyright